Can We Actually Slow Aging? What Centenarians, Metformin, and Longevity Genetics Are Teaching Us

Aging has long been treated as something that simply happens to us. A biological inevitability. A fixed trajectory that medicine can slow at the edges but never fundamentally alter. That assumption is being challenged in ways that are scientifically serious and clinically meaningful.

The question is no longer whether aging can be targeted. The question is how, and with what tools, and how soon. As a performance and optimization specialist, I find this one of the most exciting frontiers in all of medicine. What we are learning from people who live to 100 and beyond, from drugs like metformin and rapamycin, and from the genetics of exceptional longevity, is changing how I think about every patient I work with.

Let me walk you through the key ideas.

1. What Centenarians Actually Teach Us

The most important insight from studying people who live past 100 is not that they avoided disease. They did not. Centenarians still develop cancer, heart disease, and Alzheimer’s. What sets them apart is when they develop these diseases. On average, centenarians get the same chronic diseases as the rest of us, but 20 to 30 years later.

This is what researchers call a phase shift in the onset of chronic disease. The centenarian does not escape the biology of aging. They simply run it on a different, slower timeline. And when they do die, they tend to die much more quickly, with a shorter period of disability and decline before the end. This compression of morbidity, a longer healthspan followed by a faster death, is exactly the outcome we should be designing toward.

What is remarkable is that this phase shift appears to be largely genetic. Centenarians tend to engage in the same, and sometimes worse, lifestyle habits as the general population. Some smoke. Many do not exercise obsessively. Yet they live decades longer and stay healthier longer. Their genetics appear to be doing something that our behaviors, while important, cannot fully replicate.

Understanding what those genetics are doing is the key to developing interventions that might extend a similar advantage to the rest of us.

2. The GH/IGF Axis: The Most Important Longevity Pathway

More than 60 percent of centenarians studied have genomic differences that affect the growth hormone and IGF-1 axis. This is striking. The growth hormone system works as follows: the pituitary gland produces growth hormone, which signals the liver primarily to produce IGF-1. Both growth hormone and IGF-1 decline with aging. Their effects on the body are complex and sometimes contradictory, but in the context of longevity, lower IGF-1 activity in older age appears to be protective.

This seems counterintuitive. IGF-1 is associated with muscle growth, bone density, and cellular repair. Why would lower IGF-1 be associated with longer life?

The answer appears to lie in the distinction between anabolic signaling that drives growth and repair versus signaling that also drives accelerated cellular aging and cancer risk. IGF-1 activates pathways, including mTOR and PI3K, that promote cellular proliferation. In young organisms, this is highly beneficial. In older organisms, chronic activation of these same pathways appears to accelerate biological aging and increase cancer risk.

The centenarian data is consistent with this. People with genetic variants that reduce IGF-1 receptor activity tend to have lower rates of cancer, live longer, and in women, show dramatically lower rates of cognitive decline. Studies of populations with genetic growth hormone receptor deficiencies, who have very low IGF-1 levels throughout life, show remarkably reduced rates of cancer and diabetes.

This does not mean we should be trying to suppress IGF-1 at all ages and in all contexts. Growth and repair require it. The nuance lies in the timing and context of IGF-1 modulation, which is one reason why cyclic approaches to nutrition, including periodic fasting, are so interesting. Fasting dramatically reduces IGF-1 levels temporarily, potentially providing some of the longevity signaling of low IGF-1 without the permanent suppression that would impair growth and repair functions.

3. The Genetics of Exceptional Longevity: CETP, Lp(a), and FOXO3A

Beyond the GH/IGF axis, researchers have identified several other genetic signatures that concentrate in centenarian populations.

What all of these have in common is that they modulate the same interconnected pathways: insulin and IGF signaling, mTOR activation, inflammatory tone, and cellular stress response. This convergence suggests that there are a relatively small number of core biological processes that determine how quickly we age.

4. Metformin: The Most Interesting Drug in Longevity Medicine

Metformin has been used to treat type 2 diabetes since the 1950s. It is inexpensive, widely available, and has one of the longest safety records of any medication in clinical use. It also appears to do something far more interesting than simply lower blood sugar.

The mechanism involves mild inhibition of Complex I of the mitochondrial electron transport chain, which as I discussed in a previous article, alters the NADH to NAD+ ratio in the liver, slows hepatic glucose production, reduces baseline reactive oxygen species production, and activates AMPK, a cellular energy sensor that triggers a broad suite of maintenance and repair responses.

The result is a drug that appears to do many things reasonably well simultaneously:

• It lowers blood glucose.
• Reduces inflammation.
• Modifies the gut microbiome favorably.
• Activates cellular cleanup pathways.
• May slow the accumulation of the molecular damage that underlies biological aging.

The most striking piece of human evidence for metformin’s anti-aging potential came from a UK study that compared 78,000 newly diagnosed diabetic patients on metformin to 78,000 non-diabetic people not taking any diabetes medication. The diabetic patients were more obese and had more disease at baseline. Yet they had 17 percent lower mortality than the non-diabetic controls. That result, a drug making sick, overweight people outlive healthier people who are not taking it, is extraordinary and hard to explain without invoking a genuinely anti-aging mechanism.

Hundreds of studies have also associated metformin use with reduced cancer rates across multiple tumor types, reduced risk of cardiovascular events, and lower rates of dementia. The consistency of these findings across such diverse disease categories suggests that metformin is not targeting any one disease pathway specifically. It appears to be influencing the underlying biology of aging itself.

5. The TAME Trial: Proving That Aging Can Be Targeted

The TAME trial, which stands for Targeting Aging with Metformin, is one of the most important clinical studies in modern medicine. Its goal is not to show that metformin prevents any single disease. It is to show that metformin can delay the onset of a composite of age-related diseases, including cardiovascular disease, cancer, dementia, and diabetes, simultaneously.

This is a genuinely novel approach to clinical research. It treats aging itself as the target, rather than any individual disease. If successful, it would establish proof of concept for the FDA to recognize aging as an indication, opening the door to a new category of preventive medicine.

The study involves 3,000 participants aged 65 to 80, randomized to metformin or placebo for approximately five years across 14 centers in the United States. The primary endpoint is a composite of the major chronic diseases of aging. The design reflects the biological reality that aging is the root cause of all of these diseases simultaneously, and that an intervention targeting aging should affect all of them together rather than one at a time.

This paradigm shift in how we think about prevention is exactly what I try to bring to my patients at RMRM. We do not manage individual diseases in isolation. We manage the underlying biology that predisposes to all of them. The TAME trial is attempting to validate that philosophy in the largest and most rigorous way yet attempted.

6. Visceral Fat, Insulin Resistance, and the Longevity Connection

One of the most clinically important findings from aging research is the relationship between visceral fat and longevity. In animal studies, surgical removal of visceral fat produced significant increases in both lifespan and healthspan, even in the absence of any other intervention. Rats that had visceral fat removed lived 20 percent longer than controls fed the same diet. Only caloric restriction outperformed it, producing a 40 percent lifespan extension.

This is consistent with what we know about visceral fat metabolically. Visceral fat is not simply stored energy. It is an active inflammatory tissue that impairs insulin sensitivity in the liver and muscle, produces inflammatory cytokines, and disrupts the hormonal signaling that governs metabolic health. Its accumulation is one of the most reliable drivers of the insulin resistance, inflammation, and metabolic dysfunction that accelerate biological aging.

The practical implication is clear. Reducing visceral fat through diet, exercise, and targeted interventions is not just a body composition goal. It is a longevity intervention. At RMRM, we assess visceral fat and metabolic health as central components of our comprehensive diagnostics.

7. Should You Be Taking Metformin If You Are Not Diabetic?

This is one of the most common questions I get from patients interested in longevity. My answer is nuanced.

The case for metformin as a longevity intervention in non-diabetic individuals is biologically compelling. The mechanism makes sense, the animal data is consistent, and the human epidemiological data is suggestive. The TAME trial is designed to provide the definitive human evidence.

The case for caution is that the formal study in non-diabetic, non-elderly individuals has not yet been completed. There are also some concerns that metformin may blunt the adaptive response to exercise by inhibiting some of the same mitochondrial signaling that exercise activates. For highly active patients whose primary longevity strategy is vigorous exercise, this is worth considering carefully.

Frequently Asked Questions By Patients

Patient Success Stories

These patient success stories reflect our commitment to treating the root biological causes of knee pain, rather than just masking symptoms. Our mission is to help you restore function, stay active, and age stronger, so you can move better and live better every day.